FDA Clearance Tracker · P000046-S015
STAARVISC II & SHELLGEL SODIUM HYAURONATE
Last checked: Nov 20, 2026Latest source record: Mar 27, 2012 (this decision)Source: openFDAMethods & limitations
Decided
Mar 27, 2012
Approved
Time to decision
1,035 days
Received May 27, 2009. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P000046-S015
- Device name
- STAARVISC II & SHELLGEL SODIUM HYAURONATE
- Applicant
- Anika Therapeutics, Inc.
- Applicant location
- Beford, MA
- Received
- May 27, 2009
- Decided
- Mar 27, 2012
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P000046
Device type
- Device type
- AID, SURGICAL, VISCOELASTIC (LZP)
- Device class
- Class III
- Regulation
- 21 CFR 886.4275
- Specialty
- Ophthalmology
FDA's approval statement
As written in FDA's record.
APPROVAL FOR A MANUFACTURING SITE CHANGE FROM THE PREVIOUS FACILITY IN WEST CUMMINGS PARK, WOBURN, MASSACHUSETTS TO THE NEW FACILITY LOCATED IN BEDFORD, MASSACHUSETTS. IN ADDITION, THE SUPPLEMENT REQUESTED APPROVAL TO CHANGE THE TERMINAL STERILIZATION METHOD OF THE PRODUCT FROM E-BEAM CONTROLLED DEPTH STERILIZATION TO VAPORIZED HYDROGEN PEROXIDE (VHP) GAS STERILIZATION.
Source documents
Other decisions for Anika Therapeutics, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K261869 · Decided Sep 17, 2026 · 105 days after receipt
Device type: Fastener, Fixation, Nondegradable, Soft Tissue (MBI) · Orthopedic Surgery
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.